Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging

Applied Radiation and Isotopes

Volumn 82, Issue , 2013, Pages 300-307

  Sydoff, Marie ^a   Lizana, Helena ^b   Mattsson, Sören ^a   Stabin, Michael G ^c   Leide Svegborn, Sigrid ^a  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Biokinetics; Dosimetry; Lewy body dementia; Parkinson's disease

Indexed keywords

DOSIMETRY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

BIODISTRIBUTIONS; BIOKINETICS; GAMMA CAMERAS; LEWY BODY DEMENTIA; PARKINSON'S DISEASE; PLANAR IMAGING; SPECT/CT IMAGING;

NEURODEGENERATIVE DISEASES;

IOFLUPANE I 123;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE LEWY BODY DISEASE; DOSIMETRY; ECHO PLANAR IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; MALE; PARKINSONISM; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

(123)I-FP-CIT; BIOKINETICS; DOSIMETRY; LEWY BODY DEMENTIA; PARKINSON'S DISEASE;

AGED; HUMANS; IODINE RADIOISOTOPES; LEWY BODY DISEASE; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TROPANES;

EID: 84885929322     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2013.09.006     Document Type: Article

References (39)

1. Andersson, M., Johansson, L., Minarik, D., Mattsson, S., Leide-Svegborn, S., 2012. An upgrade of the internal dosimety computer program IDAC, In: Adliene, D. (Ed.), Medical physics in the Baltic states Kaunas, Lithuania, pp. 120-123.
2. Bai C.Y., Shao L., Da Silva A.J., Zhao Z. A generalized model for the conversion from CT numbers to linear attenuation coefficients. IEEE Transactions on Nuclear Science 2003, 50:1510-1515.
3. Barrett P.H., Bell B.M., Cobelli C., Golde H., Schumitzky A., Vicini P., Foster D.M. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998, 47:484-492.
4. Berker Y., Goedicke A., Kemerink G.J., Aach T., Schweizer B. Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38:2173-2185.
5. Bongartz G., Golding S.J., Jurik A.G., Leonardi M., van Persijn van Meerten E., Rodriguez R., Schneider K., Calzado A., Geleijns J., Jessen K.A., Panzer W., Shrimpton P.C., Tosi G. European guidelines for multislice computed tomography. The 2004 CT quality criteria. Appendix A: MSCT Dosimetry 2004.
6. 123I]-FP-CIT: a potent radioligand for imaging of dopamine transporters. European Journal of Nuclear Medicine 1998, 25:24-30.
7. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. Journal of Nuclear Medicine 2007, 48:359-366.
8. Booij J., Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35:424-438.
9. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. European Journal of Nuclear Medicine 1997, 24:68-71.
10. Brown S., Bailey D.L., Willowson K., Baldock C. Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT. Applied Radiation and Isotope 2008, 66:1206-1212.
11. 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004, 23:956-966.
12. Cristy M., Eckerman K.F. Specific absorbed fractions of energy at various ages from internal photon sources. Report no: ORNL/TM-8381 1987, Volumes I-VII. Oak Ridge National Laboratory.
13. de Win M.M., Habraken J.B., Reneman L., van den Brink W., den Heeten G.J., Booij J. Validation of (123)I-beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005, 30:996-1005.
14. Dewaraja Y., Li J., Koral K. Quantitative I-131 SPECT with triple energy window compton scatter correction. IEEE Transactions on Nuclear Science 1998, 45:3109-3114.
15. Dickson J.C., Tossici-Bolt L., Sera T., Erlandsson K., Varrone A., Tatsch K., Hutton B.F. The impact of reconstruction method on the quantification of DaTSCAN images. European Journal of Nuclear Medicine and Molecular Imaging 2010, 37:23-35.
16. Eshuis S.A., Jager P.L., Maguire R.P., Jonkman S., Dierckx R.A., Leenders K.L. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36:454-462.
17. Fleming J.S. A technique for the absolute measurement of activity using a gamma camera and computer. Physics in Medicine and Biology 1979, 24:176-180.
18. He B., Wahl R.L., Sgouros G., Du Y., Jacene H., Kasecamp W.R., Flinn I., Hammes R.J., Bianco J., Kahl B., Frey E.C. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Medical Physics 2009, 36:1595-1601.
19. ICRP Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53) ICRP publication 80. Annals of the ICRP 1998, 28:1-126.
20. ICRP Radiation dose to patients from radiopharmaceuticals. (Addendum 3 to ICRP Publication 53) ICRP publication. Annals of the ICRP 2008, 38:1-197.
21. Jönsson L., Ljungberg M., Strand S.E. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. Journal of Nuclear Medicine 2005, 46:1679-1686.
22. Kuikka J.T., Tupala E., Bergstrom K.A., Hiltunen J., Tiihonen J. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects. European Journal of Nuclear Medicine 1999, 26:1486-1488.
23. 123I]-FP-CIT SPET in healthy volunteers. European Journal of Nuclear Medicine 2000, 27:867-869.
24. 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. Journal of Nuclear Medicine 2009, 50:1638-1645.
25. Nadler S.B., Hidalgo J.H., Bloch T. Prediction of blood volume in normal human adults. Surgery 1962, 51:224-232.
26. National Electrical Manufacturers Association Performance Measurements of Gamma Cameras 2007, NEMA Standard Publication, (NU 1-2007).
27. Newberg A.B., Plossl K., Mozley P.D., Stubbs J.B., Wintering, Udeshi M., Alavi A., Kauppinen T., Kung H.F. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. Journal of Nuclear Medicine 2004, 45:834-841.
28. 123I-mZIENT: a novel ligand for imaging serotonin transporters. European Journal of Nuclear Medicine and Molecular Imaging 2012, 39:786-791.
29. Norrgren K., Svegborn S.L., Areberg J., Mattsson S. Accuracy of the quantification of organ activity from planar gamma camera images. Cancer Biotherapy and Radiopharmaceuticals 2003, 18:125-131.
30. Ogawa K., Harata Y., Ichihara T., Kubo A., Hashimoto S. A practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Transactions on Medical Imaging 1991, 10:408-412.
31. Pereira J.M., Stabin M.G., Lima F.R., Guimaraes M.I., Forrester J.W. Image quantification for radiation dose calculations-limitations and uncertainties. Health Physics 2010, 99:688-701.
32. Rault E., Vandenberghe S., Van Holen R., De Beenhouwer J., Staelens S., Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biotherapy and Radiopharmaceuticals 2007, 22:423-430.
33. Sjögreen K., Ljungberg M., Strand S.E. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. Journal of Nuclear Medicine 2002, 43:972-982.
34. Stabin M., Farmer A. OLINDA/EXM 2.0: the new generation dosimetry modeling code. Journal of Nuclear Medicine 2012, 53:585. (meeting abstracts).
35. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of Nuclear Medicine 2005, 46:1023-1027.
36. 123I]beta-CIT SPECT. Journal of Neurology 1998, 245:14-20.
37. 123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Movement Disorders 2007, 22:2346-2351.
38. Walker Z., Costa D.C., Walker R.W., Lee L., Livingston G., Jaros E., Perry R., McKeith I., Katona C.L. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004, 62:1568-1572.
39. Van de Wiele C., Dumont F., Dierckx R.A., Peers S.H., Thornback J.R., Slegers G., Thierens H. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. Journal of Nuclear Medicine 2001, 42:1722-1727.